MedTrace Logo

Optimizing Response in Psychosis Study

NCT00314327 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-05-16

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
  • Psychotic Disorder Not Otherwise Specified

Interventions

DRUG

long-acting injectable risperidone

One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.

Sponsors & Collaborators

  • The Zucker Hillside Hospital

    collaborator OTHER

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Delbert G Robinson, M.D. · The North Shore-Long Island Jewish Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314327 on ClinicalTrials.gov